PERSONAL INFORMATION

Dimitra Stergiopoulou



Senior IVD Development & Technology Transfer Officer, Pharmassist Ltd, Nea Ionia, Athens, Greece
+30 2106560700
d.stergiopoulou@pharmassist-cro.com, dimitrastergiopoulou@yahoo.com

Sex female | Date of birth 18/05/1991 | Nationality Greek

WORK EXPERIENCE

2025 – present

Senior IVD Development & Technology Transfer Officer/Responsible for Regulatory Compliance, R&D Department, Pharmassist Ltd, Nea Ionia, Athens, Greece

- Leading the R&D activities of the company.
- Strategic leadership of IVD product development, technology transfer, and regulatory compliance activities.
- Facilitating the production of IVD products and supporting their commercialization and market adoption.
- Preparing, reviewing, and maintaining IVDR-compliant technical documentation to support CE marking.
- Ensuring IVDR compliance, batch release oversight, regulatory documentation maintenance, post-market surveillance, vigilance reporting, and overall regulatory conformity of IVD medical devices.
- Coordination of external collaborations, validation studies, and market access activities.

Business or sector In Vitro Diagnostic (IVD) Medical Devices & Molecular Diagnostics

2021-2025

IVD Development Officer, R&D Department, Pharmassist Ltd, Nea Ionia, Athens, Greece

- Product development and process optimization of IVD products.
- Technology transfer from laboratory to pilot/manufacturing scale.
- Preparation and supporting of CE marking technical documentation.
- Support of production and commercialization activities.

Business or sector In Vitro Diagnostic (IVD) Medical Devices & Molecular Diagnostics

POSITIONS

2017 - present

Elected Board Member, Hellenic Society of Liquid Biopsy

EDUCATION AND TRAINING

2017-2023

Ph.D. in Chemistry

Department of Chemistry, National & Kapodistrian University of Athens, Athens, Greece

- Thesis title: Liquid biopsy- Molecular Diagnosis of cancer: Development of assays for the analysis of circulating tumor cells and ctDNA and clinical evaluation of their heterogeneity in breast cancer
- Advisor: Prof. Evi Lianidou
- Principal subjects: liquid biopsy, molecular diagnostic, breast cancer

2014-2017

M.Sc. in Clinical Chemistry

Department of Chemistry, National & Kapodistrian University of Athens, Athens, Greece

2009-2014

B.Sc. in Chemistry

Department of Chemistry, University of Patras, Patras, Greece

PERSONAL SKILLS

Communication skills

- Strong communication and presentation skills with scientific, clinical, regulatory, and business stakeholders.
- Ability to build and maintain relationships with international partners, academic partners, healthcare professionals

Organisational / managerial skills

- Leadership of R&D and innovation activities in the field of molecular diagnostics
- Management of product development, technology transfer, production, validation and regulatory compliance projects

Selected Seminars and Workshops (Last 3 Years)

- NoBoCap Generating Data for Technical Documentation (IVDR)
- Digital Marketing and Branding (80 hours training workshop)
- The Global Health Network, Global Health Training Centre, e-learning course “ICH Good Clinical Practices

Mother tongue

Greek

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2

ADDITIONAL INFORMATION

Publications

- Author or co-author of 11 research articles in peer-reviewed journals (stergiopoulou dimitra - Search Results - PubMed)
- ORCHID: Dimitra Stergiopoulou (0000-0002-3492-491X) - ORCID

Peer-reviewed Publications:

1. *Stergiopoulou D, Markou A, Nicolo E, Serafini MS, Zhang Q, Zhang Y, Gerratana L, Davis AA, Liu H, Gradishar WJ, Reduzzi C, Cristofanilli M, Lianidou E. ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma-cfDNA of advanced breast cancer patients: A feasibility proof-of-concept study. Mol Oncol. 2026 May 27. doi: 10.1002/1878-0261.70254. Epub ahead of print. PMID: 42201922.*

2. *Stergiopoulou D, Smilkou S, Tzanikou E, Kaklamanis L, Georgoulias V, Koukli I, Markou A, Lianidou E. Analytical and clinical validation of a novel CE-IVD kit for PIK3CA hotspot mutations in liquid biopsy samples. J Liq Biopsy. 2026 Feb 18;11:100458. doi: 10.1016/j.jlb.2026.100458. PMID: 41756001; PMCID: PMC12933448.*

3. *Smilkou S, Ntzifa A, Stergiopoulou D, Georgoulias V, Lianidou E. Multiplex detection of ten ESR1 mutations and AKT1 E17K in breast cancer using digital PCR. J Liq Biopsy. 2024 Mar 30:5:100154. doi: 10.1016/j.jlb.2024.100154. eCollection 2024 Sep.*

4. *Stergiopoulou D, Georgoulias V, Markou A, Lianidou E. Development and validation of a multi-marker liquid bead array assay for the simultaneous detection of PIK3CA and ESR1 hotspot mutations in single circulating tumor cells (CTCs). Heliyon. 2024 Sep 12;10(19):e37873. doi: 10.1016/j.heliyon.2024.e37873. eCollection 2024 Oct 15.*

5. *Stergiopoulou D, Smilkou S, Georgoulias V, Kaklamanis L, Lianidou E, Markou A. Development and Validation of a Novel Dual-Drop-off ddPCR Assay for the Simultaneous Detection of Ten Hotspots PIK3CA Mutations. Anal Chem. 2023 Sep 19;95(37):14068-14076. doi: 10.1021/acs.analchem.3c02692. Epub 2023 Sep 8*

6. *Markou A, Londra D, Stergiopoulou D, Vamvakaris I, Potaris K, Pateras IS, Kotsakis A, Georgoulias V, Lianidou E, Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer, Cancers (Basel). 2023 Mar 21;15(6):1877. doi: 10.3390/cancers15061877.*

7. *Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, Kallergi G, Georgoulias V, Lianidou E, Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer, Sci Rep. 2023 Jan 23;13(1):1258. doi: 10.1038/s41598-022-25400-1.*

8. *Stergiopoulou D, Markou A, Giannopoulou L, Buderath P, Balgkouranidou I, Xenidis N, Kakolyris S, Kasimir-Bauer S, Lianidou E, Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients, Cancers (Basel). 2022 Aug 4;14(15):3790. doi: 10.3390/cancers14153790.*

9. *Tserpeli V, Stergiopoulou D, Londra D, Giannopoulou L, Buderath P, Balgkouranidou I, Xenidis N, Grech C, Obermayr E, Zeillinger R, Pavlakis K, Rampias T, Kakolyris S, Kasimir-Bauer S, Lianidou ES, Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer, Cancers (Basel). 2021 Dec 21;14(1):4. doi: 10.3390/cancers14010004.*

10. *Tsitsilonis OE, Paraskevis D, Lianidou E, Terpos E, Akalestos A, Pierros V, Kostaki EG, Kastritis E, Moutsatsou P, Politou M, Scorilas A, Sphicopoulos T, Thomaidis N, Trougakos IP, Tsakris A, Voulgaris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Tsiodras S, Dimopoulos MA, Sfikakis PP, SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response, Vaccines (Basel). 2021 Mar 2;9(3):207, doi: 10.3390/vaccines9030207.*

11. *Tsitsilonis, O.E.; Paraskevis, D.; Lianidou, E.; Pierros, V.; Akalestos, A.; Kastritis, E.; Moutsatsou, P.; Scorilas, A.; Sphicopoulos, T.; Terpos, E.; Thomaidis, N.; Tsakris, A.; Voulgaris, N.; Daskalaki, C.C.; Evangelakou, Z.; Fouki, C.; Gianniou, D.D.; Gumeni, S.; Kostaki, E.-G.; Kostopoulos, I.V.; Manola, M.S.; Orologas-Stavrou, N.; Panteli, C.; Papanagnou, E.-D.; Rousakis, P.; Sklirou, A.D.; Smilkou, S.; Stergiopoulou, D.; Trougakos, I.P.; Tsiodras, S.; Sfikakis, P.P.; Dimopoulos, M.-A. Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life 2020, 10, 214. doi: 10.3390/life10090214.*

12. *Stergiopoulou D., Markou A., Tzanikou E., Ladas I., Makrigiorgos G.M., Georgoulias V., Lianidou E. ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies, Strategies for Isolation and Phenotypic, Genetic, and Functional Characterization of Circulating Tumor Cells Cancers 2021, 13(3), 556; doi:10.3390/cancers13030556.*

Invited Presentations

Invited speaker and presenter at multiple national and international conferences, scientific meetings, and industry events.

Awards / Scholarships

2019 Poster Award: 4th Advances in Circulating Tumour Cells (ACTC) 2019, Corfu, Greece. Stergiopoulou D., Markou A., Tzanikou E., Oomen L., Broekmaat J., Tibbe A., Georgoulias V., Lianidou E. "Detection of *PIK3CA* hotspot mutations in single circulating tumor cells using a combination of NAPA (NaME-Pro-assisted ARMS) and Droplet Digital PCR".

2017 Received financial support through a three-year scholarship awarded within the Stavros Niarchos Foundation-funded research programme “Liquid Biopsy - Molecular Diagnosis of Cancer under the supervision of Prof. Evi Lianidou

Bibliometric Indicators

Google Scholar

- h-index: 8
- i10-index: 8
- citations: 222